INT181107

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.73
First Reported 2004
Last Reported 2010
Negated 9
Speculated 1
Reported most in Body
Documents 45
Total Number 53
Disease Relevance 44.33
Pain Relevance 1.96

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Epcam)
Anatomy Link Frequency
epithelium 7
body 3
hematopoietic cells 2
colon 1
bone marrow 1
Epcam (Mus musculus)
Pain Link Frequency Relevance Heat
Bile 16 98.28 Very High Very High Very High
Inflammation 49 98.00 Very High Very High Very High
metalloproteinase 25 90.84 High High
chemokine 56 85.40 High High
cytokine 92 84.92 Quite High
abdominal pain 27 81.84 Quite High
anesthesia 36 78.48 Quite High
Inflammatory response 12 69.52 Quite High
Pain 31 67.16 Quite High
nud 24 38.00 Quite Low
Disease Link Frequency Relevance Heat
Carcinoma 314 100.00 Very High Very High Very High
Adhesions 128 100.00 Very High Very High Very High
Cancer 2642 99.86 Very High Very High Very High
Colon Cancer 179 99.86 Very High Very High Very High
Melanoma 63 99.84 Very High Very High Very High
Malignant Neoplastic Disease 208 99.40 Very High Very High Very High
Breast Cancer 775 99.00 Very High Very High Very High
Stomach Cancer 492 98.96 Very High Very High Very High
Pressure And Volume Under Development 416 98.78 Very High Very High Very High
Apoptosis 81 98.72 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the case of CTCs that express low or no EpCAM and low or no CK, we need different strategies to enrich and target the correct cells.
Neg (no) Gene_expression (express) of EpCAM
1) Confidence 0.73 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575542 Disease Relevance 0.47 Pain Relevance 0
These variations may be a result of the low frequency of CTCs or the heterogeneity of CK and EpCAM expression in the CTCs, resulting in certain types of CTCs being missed by one or the another enrichment methods.
Gene_expression (expression) of EpCAM
2) Confidence 0.73 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575542 Disease Relevance 0.15 Pain Relevance 0
Since most of the CTCs express both CK and EpCAM [51], this new CTC-enrichment strategy will consistently enrich most CTCs with CK+&EpCAM+, CK-/low&EpCAM+ or CK+&EpCAM-/low.
Gene_expression (express) of EpCAM
3) Confidence 0.73 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575542 Disease Relevance 0.06 Pain Relevance 0
Several authors reported the heterogeneous expression of EpCAM in mammary carcinomas [15,19]; downregulation of EpCAM was reported for disseminated tumor cells in bone marrow and CTCs in peripheral blood [15,19,48].
Gene_expression (expression) of EpCAM in blood associated with cancer and carcinoma
4) Confidence 0.73 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575542 Disease Relevance 0.50 Pain Relevance 0
Because CK and EpCAM are both heterogeneously expressed on tumor cells (Figures 3 and 4(d)) [15,19,48], the enrichment with the combined antibodies may increase the sensitivity and reproducibility by the compensation effect of biomarkers from each other.
Gene_expression (expressed) of EpCAM associated with cancer
5) Confidence 0.73 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575542 Disease Relevance 0.18 Pain Relevance 0
The differential expression of CK and EpCAM on the same cell will be the key to ensure that no target cells are missed.
Gene_expression (expression) of EpCAM
6) Confidence 0.73 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575542 Disease Relevance 0.50 Pain Relevance 0
Since EpCAM is not equally expressed in all tumor cells [15,19], ideally, it would make better sense to use the same antibodies to enrich and identify CTCs.
Neg (not) Gene_expression (expressed) of EpCAM associated with cancer
7) Confidence 0.73 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575542 Disease Relevance 0.41 Pain Relevance 0
Similar results were reported in bone marrow samples involving a total of 26 CK+ tumor cells, of which none of them co-expressed EpCAM after chemotherapy.
Neg (none) Gene_expression (expressed) of EpCAM in bone marrow associated with cancer
8) Confidence 0.63 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575542 Disease Relevance 0.46 Pain Relevance 0
As EpCAM is also expressed in normal epithelium [16], the rationale for i.p. application was to achieve high local concentrations and thus diminish potential negative side-effects.
Gene_expression (expressed) of EpCAM in epithelium
9) Confidence 0.60 Published 2010 Journal British Journal of Clinical Pharmacology Section Body Doc Link PMC2878603 Disease Relevance 1.46 Pain Relevance 0.11
The majority of these tumour cells (70–100%) express EpCAM [7–11].
Gene_expression (express) of EpCAM associated with cancer
10) Confidence 0.60 Published 2010 Journal British Journal of Clinical Pharmacology Section Body Doc Link PMC2878603 Disease Relevance 1.39 Pain Relevance 0
The expression level for EpCAM may vary between colorectal and breast cancer [35], or within breast cancer primary tumors in a bimodal (low or high) manner [36].
Gene_expression (expression) of EpCAM associated with cancer and breast cancer
11) Confidence 0.60 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC549166 Disease Relevance 0.98 Pain Relevance 0
However, the specificity of the method is hampered by the fact that subpopulations of hematopoietic cells and erythroid progenitors also express EpCAM and copurify with tumor cells in the sample.
Gene_expression (express) of EpCAM in hematopoietic cells associated with cancer
12) Confidence 0.60 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC549166 Disease Relevance 0.82 Pain Relevance 0
The expression of the EpCAM antigen might be modulated during the proliferation and dedifferentiation steps that occur during the progression of cancer.
Gene_expression (expression) of EpCAM associated with cancer
13) Confidence 0.60 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC549166 Disease Relevance 1.12 Pain Relevance 0
We have previously reported the limitations of the EpCAM-based IM technique, due to the ability of some BM cells to express EpCAM antigens and to contaminate the immunopurified fraction [16].
Gene_expression (express) of EpCAM
14) Confidence 0.60 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC549166 Disease Relevance 1.42 Pain Relevance 0.04
Besides the difference in sensitivity due to different enrichment protocols, we suggest that both methods may detect different tumor cell subpopulations that differentially express the CK and EpCAM antigens.
Gene_expression (express) of EpCAM associated with cancer
15) Confidence 0.60 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC549166 Disease Relevance 0.58 Pain Relevance 0
One such target, epithelial cell adhesion molecule (EpCAM or CD326), whose normal function is to mediate epithelium-specific, homotypic cell-cell adhesions (Litvinov et al 1994, 1997), is highly expressed in a variety of carcinomas (Balzar et al 1999; Winter et al 2003; Went et al 2004), including squamous cell carcinoma of the tongue (Yanamoto et al 2007), esophagus (Stoecklein et al 2006) and oral cavity (Laimer et al 2008), and thus represents an ideal target for immunotherapy.
Gene_expression (expressed) of CD326 in epithelium associated with carcinoma, skin cancer and adhesions
16) Confidence 0.58 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761172 Disease Relevance 0.60 Pain Relevance 0
However, some tumor cells express low or no EpCAM.
Neg (no) Gene_expression (express) of EpCAM associated with cancer
17) Confidence 0.56 Published 2008 Journal Breast Cancer Res Section Abstract Doc Link PMC2575542 Disease Relevance 0.75 Pain Relevance 0
To compensate for low or no expression of EpCAM and CK, we also developed an assay with a combination of anti-CK and anti-EpCAM antibodies that allows the enrichment of all types of CTCs including CK+&EpCAM+, CK+&EpCAM-/low and CK-/low&EpCAM+ tumor cells.
Neg (no) Gene_expression (expression) of EpCAM associated with cancer
18) Confidence 0.56 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575542 Disease Relevance 0.53 Pain Relevance 0
The CellSearch™ system represents an example of CTC enrichment with anti-EpCAM and detection with CK.
Gene_expression (detection) of EpCAM
19) Confidence 0.56 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575542 Disease Relevance 0.17 Pain Relevance 0
This trifunctionality leads to effective destruction of EpCAM-positive tumour cells even at antibody concentrations in the pg ml?
Gene_expression (destruction) of EpCAM associated with cancer
20) Confidence 0.52 Published 2010 Journal British Journal of Clinical Pharmacology Section Body Doc Link PMC2878603 Disease Relevance 0.95 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox